Skip to main content

Table 3 Clinical outcomes by randomized treatment during ACCORD-lipid trial, ACCORDION and full follow-up period

From: Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

EventDuring ACCORD-lipid (short-term effect)PPost-trial only (legacy effect)PFull follow-up (long-term effect)P
Rate of events (100 person-years)Hazard Ratio (95% CI)Rate of events (100 person-years)Hazard ratio (95% CI)Rate of events (100 person-years)Hazard ratio (95% CI)
FibratePlaceboFibratePlaceboFibratePlacebo
All-cause mortality1.542.260.68 (0.44, 1.04)0.073.054.430.65 (0.45, 0.94)0.022.233.240.68 (0.52, 0.88)< 0.01
CVD mortality0.671.280.53 (0.29, 0.98)0.041.121.530.77 (0.43, 1.39)0.380.881.390.63 (0.42, 0.95)0.03
Nonfatal MI1.762.450.72 (0.47, 1.09)0.120.851.070.74 (0.33, 1.66)0.471.401.910.74 (0.51, 1.06)0.10
Stroke0.560.740.75 (0.36, 1.56)0.440.560.550.87 (0.33, 2.29)0.780.580.670.88 (0.5, 1.56)0.66
CHF1.391.510.90 (0.55, 1.47)0.680.650.930.69 (0.30, 1.57)0.381.071.270.82 (0.54, 1.24)0.35
Major CHD3.014.600.65 (0.48, 0.90)0.012.173.270.64 (0.40, 1.03)0.072.674.090.66 (0.51, 0.86)< 0.01
  1. MI myocardial infarction, CHF congestive heart failure, CHD coronary heart disease